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Abstract 
Background: We present here a case of haemorrhagic brain infarction in a middle-aged 
and physically active male, who had never smoked. This case report aims to remind the 
internist and neurologist to bear in mind unusual aetiologies of brain infarcts in patients 
without classical cardiovascular risk factors.  
Case Description: A 49-year-old male with pulmonary asthma and a prior history of nasal 
polyps had a wake-up stroke with left-sided symptoms and speech disturbance. A head 
MRI and MR angiography revealed a recent haemorrhagic infarct in the right putamen 
and corona radiata. The left hemiparesis progressed to sensory-motor hemiplegia on the 
4th day. In the head CT, it was shown that the haemorrhagic infarct had progressed to a 
large haematoma. A pansinusitis was also diagnosed. The aetiological investigations 
revealed a minor atrial septal defect (ASD) with shunting and a heterozygotic clotting 
factor V R506Q mutation. A remarkable blood eosinophilia of 9.80 E9/l (42%) together 
with fever, sinusitis, wide-spread bilateral nodular pulmonary infiltrates that did not 
respond to wide-spectrum antimicrobial treatment, positive anti-neutrophilic 
cytoplasmic antibodies, a high myeloperoxidase antibody level and slightly positive anti-
proteinase 3 antibodies suggested the diagnosis of Churg-Strauss syndrome. These 
inflammatory symptoms and findings promptly responded to treatment with 
corticosteroids and cyclophosphamide.   
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Conclusions: Even after the concomitant findings of the low risk factors, i.e. small ASD 
and heterozygotic clotting factor mutation, continued search for the final aetiology of 
stroke revealed Churg-Strauss syndrome, which was the key to the treatment. 
 
Case Report 
In mid-January 2010, a 49-year-old male with pulmonary asthma and a prior history of nasal polyps 
woke up at 00.30 at night with a feeling of tongue swollenness. Upon standing up, he noticed 
paraesthesia of the left hand and a left facial droop. When the emergency medical staff arrived, he was 
sitting, his speech was blurred, and the muscle strength of his extremities was unaffected. Due to the 
wake-up nature of the mild hemiparesis, he was not considered a candidate for thrombolysis treatment 
when he was pre-notified to the neurological emergency by the emergency medical staff. 
The patient had never smoked, and his previous medical history was free of cardiac symptoms, 
hypertension, hyperlipidaemia, diabetes, or migraine. He was in excellent physical condition and had 
done a 10-km cross-country skiing trip 2 days before. In addition, he had previously run several 
marathons. Physical examination at the emergency department revealed a slight pronation of the left 
arm and a mild slowness of the diadochokinesia of the left hand together with a residual paresis and 
paraesthesia of the lower facial area. The head CT scan showed no findings, and neither did the plain 
chest X-ray. The patient was admitted to a neurological ward with a working hypothesis of brain stem 
infarction, and acetylsalicylic acid was administered at a loading dose of 250 mg orally, which was 
continued at a dose of 100 mg daily. 
The next day, a head MRI and MR angiography (MRA) revealed a fresh minor infarction at the 
corona radiata on a FLAIR sequence (fig. 1a), with a diffusion-weighted image showing restricted 
diffusion of the lesion, consistent with an infarct (fig. 1b), as well as a 3-mm hemosiderin ring at the 
right putamen (fig. 1c). The MRA of the intracranial and neck vessels was unremarkable. The left 
hemiparesis progressed to sensory-motor hemiplegia on the 4th day. The head CT scan showed an 
expansive right-sided intracerebral haemorrhage in the basal ganglia extending to the corona radiata 
(fig. 1d). 
The ancillary aetiological studies of the haemorrhagic infarction included transcranial Doppler 
sonography, which showed right-sided microemboli that were increased after a Valsalva manoeuvre. 
Correspondingly, a minor atrial septal defect (ASD) with shunting was suspected at transthoracic 
echocardiography. The patient had a heterozygotic clotting factor V R506Q mutation, i.e. activated 
protein C (APC) resistance. 
On admission, the blood chemistry showed mild leucocytosis of 9.2 E9/l and the C-reactive protein 
(CRP) level was 7 mg/l. Head CT scan revealed asymptomatic pansinusitis of the frontal, ethmoidal, and 
left sphenoidal cavities, and the patient was given oral amoxycillin. However, during the first 10 days, 
the CRP level rose up to 185 mg/l, and the leucocyte count up to 20.7 E9/l. Chest X-ray remained 
normal. Maxillary puncture was performed, and the bacterial cultures of the pus grew coliforms and 
local normal flora, susceptible to the antimicrobials being used. The empiric antimicrobial therapy was 
changed to cefuroxime and metronidazole and then piperacillin plus tazobactam, without any response 
in the inflammatory parameters. The patient had high fever (up to 38.8°C) and intense muscle pain, but 
blood cultures were negative. Consequently, contrast-enhanced body CT was performed and showed 
wide-spread bilateral nodular chest infiltrates in all pulmonary lobes and reactive lymph nodes in the 
upper mediastinal area. Bronchoalveolar lavage was not possible due to the haemorrhagic brain 
infarction. 
An infectious diseases specialist was consulted, and further diagnostic work-up showed a remarkable 
blood eosinophilia of 4.89–9.8 E9/l (30–42%) (fig. 2), positive anti-neutrophilic cytoplasmic antibodies 
(P-ANCA) antibody titer (200; reference value <20), a high serum myeloperoxidase antibody level (63.4 
IU/ml; reference value <6) and slightly positive serum proteinase 3 antibodies (9.9 IU/ml; reference 
value <4), slightly decreased levels of serum IgA (0.74 g/l; reference value 0.88–4.84), normal IgG, but 
elevated IgG4 (4.45 g/l; reference value 0.08–1.4) (table 1). The patient had never visited the tropics. 
Also, stool examinations were negative for parasites including amoeba staining and Strongyloides 
culture, and the patient did not show serum antibodies against Trypanosoma, Toxocara, Echinococcus,  
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Fasciola, schistosoma, Filaria, Strongyloides or Toxoplasma. Additionally, serologic tests for HIV, 
cytomegalovirus, Epstein-Barr virus, human herpes virus 1 and 2, and for hepatitis A, B and C were all 
negative. The patient did not have anti-phospholipid antibodies. HLA typing showed HLA-B*35 allele 
(heterozygous mutation). 
The bone marrow aspirate revealed normal morphology and relatively strong eosinophilia, and the 
chromosomal investigation was unremarkable. Interferon gamma release assay for M. tuberculosis was 
negative. 
The combination of asthma, sinusitis, history of nasal polyps, and eosinophilia, together with the 
detection of antinuclear and anti-neutrophilic antibodies evoked the suspicion of Churg-Strauss 
syndrome, leading to the treatment decision of a 3-day therapy with intravenous pulse 
methylprednisolone (1 g/day). The blood eosinophils and ANCA antibodies were undetectable 3 days 
and 1 month after treatment onset, respectively (fig. 2). Beta-lactam antimicrobials were changed to 
clindamycin together with ciprofloxacin. There were no skin or joint manifestations, cardiac 
dysfunction or signs of peripheral neuropathy at the time of the diagnosis, nor did the head MRA 
demonstrate findings that would have confirmed the CNS vasculitis as aetiology of the haemorrhagic 
brain infarction. The cerebrospinal fluid was not investigated, nor was a brain biopsy taken to confirm 
the CNS vasculitis, because of the urgent need to start immunomodulatory therapy due to the suspicion 
of Churg-Strauss syndrome with a cytotoxically high eosinophil level. Nasal mucous membrane biopsy 
did not confirm vasculitis either. No renal biopsy was performed; however, the CT scan showed wedge-
like lesions, suggesting renal infarcts. In addition, urine examination showed slight microscopic 
haematuria and proteinuria (834 mg/l). Alanine aminotransferase temporarily increased to 509 U/l. 
After  treatment with high-dose corticosteroids i.v. for 3 days, the patient was first given 
cyclophosphamide for 2 weeks together with oral prednisolone, until he developed prolonged 
neutropenia and fever. During that time, he also developed ileus, which was managed conservatively. 
Later, a colonoscopy was performed which showed a rectal tubular polyp but no ischaemia or 
inflammatory lesions. At that time, he was started on immunoglobulins (0.4 g/kg i.v.) given every 3 
weeks as an additive immunomodulatory treatment together with oral corticosteroids (fig. 2). 
Three months after the start of the immunosuppressive treatment, while on oral corticosteroids 
(prednisolone 20 + 10 mg) and azathioprine (100 mg), the patient suddenly and unfortunately 
developed peritonitis. A laparoscopy showed an ileal perforation, but there were no histological changes 
suggesting vasculitis. Though taken during immunosuppressive treatment, electroneuromyography 
(ENMG) suggested vasculitis-like neuropathic changes, but an undiagnostic muscle biopsy from the 
right vastus lateralis muscle contained only subcutaneous tissue with no signs of necrotizing vasculitis 
or eosinophils. 
The left-sided sensory-motor hemiplegia and the neuropsychological symptoms indicated physio- 
and ergotherapeutic as well as neuropsychological rehabilitation, which was actively continued after the 
initial complications. The patient was still in a neurological rehabilitation institution almost 7 months 
after the ictus. 
Discussion 
Here, we report a case of haemorrhagic brain infarction in a middle-aged male, who 
had no typical risk factors. Intense investigations, however, revealed a few but rare 
putative predisposing factors. He had an ASD and a heterozygotic clotting factor V 
R506Q mutation, i.e. APC resistance, which could well have been the sole underlying 
cause of the infarct. However, high eosinophilic leucocytosis, fever, muscle pain, resistant 
sinusitis and pneumonic infiltrates led to the suspicion of a small vessel vasculitis, which 
was supported by the presence of P-ANCA. The diagnosis could not be confirmed by 
biopsies from nasal mucosa, gut or subcutaneous tissue taken during immunosuppressive 
treatment. The patient’s inflammatory disease responded rapidly to treatment, but he still 
needed neurological rehabilitation 7 months afterwards.  
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There has been an increasing emphasis on the role of patent foramen ovale (PFO) in 
the genesis of ischaemic stroke during the last decade. A recent meta-analysis 
summarized that PFO is significantly associated with stroke in patients younger than 60 
years of age, in particular in the subgroup of young patients with cryptogenic stroke. 
Several factors have been suggested to increase the risk for stroke or recurrent stroke in 
patients with a PFO: these include a younger age, the association with atrial septal 
aneurysm, the presence of a right-to-left shunt at rest, the size of the PFO, and the 
association with thrombophilic conditions [1]. Our patient had 3 out of these 5 factors. 
The most frequently encountered hereditary hypercoagulable states are APC resistance 
due to factor V Leiden mutation, prothrombin 20210A mutation, protein C deficiency, 
protein S deficiency, and AT III deficiency. Patients with a hypercoagulable state typically 
present with a venous thrombosis and, less commonly, arterial thrombosis including 
ischaemic stroke may occur. Paradoxical cerebral arterial emboli may be due to deep 
venous/pelvic thrombi in patients with an ASD or a patent foramen ovale [2]. The 
inherited thrombophilia has often been suggested to be coincidental rather than causal in 
stroke patients [3]. The investigations in our patient did not include a search for deep vein 
thrombosis or pelvic thrombosis, which leaves the aetiological role of heterozygotic factor 
V Leiden mutation and ASD uncertain. In addition, the initially small-sized ischaemic 
brain infarct which occurred at rest was not typical for cardioembolism. The high 
eosinophil count most obviously also contributed to thrombophilia in our patient. 
The spectrum of small vessel vasculitides includes Wegener’s granulomatosis, 
microscopic polyangiitis, Churg-Strauss syndrome, Henoch-Schönlein purpura, 
cutaneous leucocytoclastic vasculitis and essential cryoglobulinaemic vasculitis [4]. The 
first 3 conditions are characterized by the presence of circulating ANCAs [5]. The ANCA 
autoantibodies have been suggested to play an in vivo pathogenetic role by having an 
effect on neutrophil function. In patients with necrotizing vasculitis, ANCA-induced 
release of toxic oxygen radicals and noxious granule enzymes from cytokine-primed 
neutrophils has been proposed to mediate vascular inflammation [6]. Also, the HLA-B*35 
allele positivity detected in our patient has been associated for example with endothelial 
dysfunction, increased mononuclear cell apoptosis and rapid progression in HIV 
infection [7–9], which may have played a role in the inflammatory cascade. 
The Churg-Strauss syndrome is the most infrequent of the ANCA vasculitides. ANCA 
vasculitis mostly present at middle age, as in the present case. The primary systemic 
vasculitis damages the vessel walls, which leads either to obstruction, stenosis, or 
dilatation, resulting in ischaemic or bleeding consequences [4]. In the Churg-Strauss 
syndrome, a granulomatous inflammation may also be present in addition to vasculitis. 
The diagnosis of small vessel vasculitis should preferably rely on both clinical findings 
and histopathological examination of the organ involved. In the present case, the clinical 
combination of asthma, sinusitis, history of nasal polyps, eosinophilia, and pulmonary 
findings together with the detection of antinuclear and anti-neutrophilic antibodies 
served as a substitute for a diagnostic biopsy from the affected organ. In addition, ENMG, 
kidney imaging and urine sediment findings were slightly suggestive of vasculitis. A 
previous case series included brain infarcts as a manifestation or complication of Churg-
Strauss syndrome in 3 patients [10]. One case report described intracerebral haemorrhage 
as a rare sequel of Churg-Strauss syndrome [11], and another reported an elderly woman 
with multiple cerebral infarctions and hypereosinophilia with assumed cardiac 
involvement and multiple cerebral infarctions due to cardiac embolism [12].  
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Cyclophosphamide combined with glucocorticoids is the standard therapy for 
remission induction in generalized ANCA-associated vasculitis [13, 14]. These treatments 
were indicated also in our patient due to the severe CNS manifestation and systemic 
multi-organ findings (including pulmonary infiltrates). The fact that the high levels of 
eosinophilia and autoantibodies promptly responded to immunosuppressive treatment is 
also supportive for the Churg-Strauss syndrome diagnosis. Ileal perforation may have 
been an iatrogenic complication, but due to the absence of any other known predisposing 
factors, gut vasculitis was suspected as an underlying cause despite normal histology of 
the gut biopsy during immunosuppressive treatment. 
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Table 1. The autoantibodies at the time of diagnosis of Churg-Strauss syndrome and after high-dose IV 
steroid treatment 
Antoantibodies Value  at 
1 week 
<Reference  <Value at  
<1 month 
S-ANCA      
S-Pr3AbG  09.9 IU/ml  0<4  0<2 IU/ml 
S-MPOAbG 63.4  IU/ml 0<6  0<2 IU/ml 
S-C-ANCIF  .<20 titer  <20  <20 titer 
S-P-ANCIF  .200 titer  <20  <20 titer 
S-ANAAb  .080 <80  <80 
 
 
 
 
 
Fig. 1. Head MRI on admission (a–c) and control head CT scan after symptom progression on day 4 
(d). a An axial FLAIR image showing an acute infarct in the right putamen (arrow). b A diffusion-
weighted image demonstrating restricted diffusion of the lesion, consistent with an infarct. c A small 
haemorrhage (black dot) is noted within the infarcted area in a T2*-weighted image. d Progression of 
the haemorrhagic transformation in the putamen on day 4 in CT. 
 
  
Case Rep Neurol 2011;3:32–38 
DOI: 10.1159/000323214 
Published online: 
January 21, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–680X 
www.karger.com/crn 
 
 
37
 
Fig. 2. Blood eosinophil count (E9/l) and CRP level (mg/l) in relation to the treatments. 
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